Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Macrogen Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and is located within 1 distinct art unit. This singular focus suggests that the company's current patenting efforts are concentrated in a specific technical niche, allowing for a deep dive into the relevant prior art.
The busiest examiner is EIX, EMILY FAY, who is responsible for 1 busiest examiner pending office action. Since there is only 1 pending office action in total, this examiner is the sole official currently reviewing the company's active applications. Strategy should be tailored specifically to the examination patterns of EIX, EMILY FAY to ensure a favorable outcome in the Biotechnology & Pharmaceuticals field.
The involvement of only 1 distinct art unit simplifies the prosecution landscape for Macrogen Inc. by ensuring a uniform application of examination guidelines. With a single active case, the company can focus its resources on addressing the specific concerns raised by the 1 distinct examiner. This centralized approach minimizes the complexity of managing multiple active patent applications and streamlines the path toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EIX, EMILY FAY | 1 | 45.9% | +73.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17961863 | COMPOSITION AND METHOD FOR AN ANTIBIOTIC-INDUCING IMBALANCE IN MICROBIOTA | EIX, EMILY FAY | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17961863 | COMPOSITION AND METHOD FOR AN ANTIBIOTIC-INDUCING IMBALANCE IN MICROBIOTA | EIX, EMILY FAY | 1653 | §103 | Final Rejection | — | Pending | Oct 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMacrogen Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Emily Fay Eix has the most, with 1 of Macrogen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.